Rossari Biotech Ltd (ROSSARI) Q2FY27 Management Mirror - Sep-2026 Qtr
H1 FY27 Revenue Growth of 20% Exceeds ~15% Guided in Jun'26 Qtr; FY27 Now Upgraded to Mid-to-High Teens
In the Sep'26 Qtr, the company reported Q2 FY27 revenue of Rs. 697.6 crore with H1 FY27 revenue closing at close to Rs. 1,400 crore, reflecting 20% YoY growth. This performance exceeded the ~15% annualized top-line growth guidance reiterated in the Jun'26 Qtr concall. Consequently, management upgraded its full-year FY27 revenue growth guidance to a mid-teen to high-teen range from the initially assessed 12% to 14%, despite ongoing geopolitical, logistics, and demand headwinds anticipated in H2 FY27. Furthermore, management expects FY28 to deliver stronger performance supported by new raw material allocations, aiming to more than double total company revenue over the next four years.
4 more themes on the ELITE plan.